脑转移瘤的肿瘤免疫微环境：迈向抗肿瘤免疫

Tumor Immune Microenvironment of Brain Metastases: Toward Unlocking Antitumor Immunity

（IF: Cancer Discov., 39.397）

Brain metastasis (BrM) is a devastating complication of solid tumors associated with poor outcomes. Immune-checkpoint inhibitors (ICI) have revolutionized the treatment of cancer, but determinants of response are incompletely understood. Given the rising incidence of BrM, improved understanding of immunobiologic principles unique to the central nervous system (CNS) and dissection of those that govern the activity of ICIs are paramount toward unlocking BrM-specific antitumor immunity. In this review, we seek to discuss the current clinical landscape of ICI activity in the CNS and CNS immunobiology, and we focus, in particular, on the role of glial cells in the CNS immune response to BrM.

脑转移（BrM）是与预后不良的实体瘤相关的严重并发症。免疫检查点抑制剂（ICI）已经彻底改变了癌症的治疗，但对反应的决定因素尚不完全清晰。鉴于BrM的发病率不断上升，提高对中枢神经系统（CNS）特有的免疫生物学原理的理解，及对控制ICI活动原理的剖析，对于解锁BrM特异性抗肿瘤免疫至关重要。在这篇综述中，我们试图讨论ICI活动在CNS和CNS免疫生物学中的当前临床情况，尤其是胶质细胞在CNS对BrM免疫反应中的作用。

Significance 意义

There is an urgent need to improve patient selection for and clinical activity of ICIs in patients with cancer with concomitant BrM. Increased understanding of the unique immunobiologic principles that govern response to ICIs in the CNS is critical toward identifying targets in the tumor microenvironment that may potentiate antitumor immunity.

对于合并BrM的癌症患者，迫切需要改进ICIs的患者选择和临床活动。增加对控制CNS中对ICIs反应的独特免疫生物学原理的理解，对于确定肿瘤微环境中可能增强抗肿瘤免疫的靶点至关重要。